Biotech stock KalVista has soared recently, as the firm looks to fundamentally change the treatment landscape for HAE ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.46, a high estimate of $32.00, ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...